Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita(burosumab-twza) for the Treatment of Children and Adults with X-Linked Hypophosphatemia (XLH)

NOVATO, California, TOKYO and LONDON, April 17, 2018 /PRNewswire/ -- First Approved Therapy for XLH in the U.S.; Only Treatment that Targets the Underlying Cause of this Rare, Hereditary, Lifelong...

More From BioPortfolio on "Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita(burosumab-twza) for the Treatment of Children and Adults with X-Linked Hypophosphatemia (XLH)"